1 Sanjay Gandhi Post Graduate Institute of Medical Sciences, Dept. of Endocrinology, Rae Bareli Road, Lucknow, Uttar Pradesh, India.
2 Amsterdam UMC - Locatie VUMC, Endocrinology, De Boelelaan 1117, 1118, 1081 HV, Amsterdam, Noord-Holland, Netherlands.
3 Duke-NUS Medical School, Cardiovascular and Metabolic Disorders Program, 8 College Road, Level 8, Singapore.
Non-alcoholic fatty liver disease (NAFLD) represents a spectrum of hepatic disorders that ranges from excess lipid storage in the liver (hepatosteatosis) to progressive nonalcoholic steatohepatitis (NASH) which can lead to cirrhosis and hepatocellular cancer. First described in the clinical literature 40 years ago, NAFLD now has become a pandemic that affects approximately 25% adults worldwide with its prevalence estimated to be 60%-80% in patients with type II diabetes milletus (DM) and obesity (1).